Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hypothalamic nuclei, including the arcuate nucleus, the paraventricular hypothalamic area, and the dorsomedial hypothalamus, integrate glucagon-like peptide-1 (GLP-1) signals to regulate feeding behavior, body weight, and glucose homeostasis. Recent advances have revealed that both endogenous GLP-1, produced by preproglucagon neurons in the nucleus tractus solitarius, and pharmacological GLP-1 receptor agonists (GLP-1RAs) engage distinct and overlapping hypothalamic circuits. However, the mechanisms underlying these effects involve circuit redundancy, diverse modes of signal integration, and context-dependent actions of different GLP-1R ligands. In this review, we propose a conceptual framework highlighting opportunities for future research and the therapeutic potential of targeting central GLP-1 pathways for obesity treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/endocr/bqaf125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.
Dermatol Ther (Heidelb)
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Bologna, Italy.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.
View Article and Find Full Text PDFSuper effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative.
Diabetologia
September 2025
Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice.
Diabetologia
September 2025
Walther Straub Institute of Pharmacology and Toxicology, LMU Munich, Munich, Germany.
Aims/hypothesis: Unimolecular peptides targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) have been shown to improve glycaemic management in both mice and humans. Yet the identity of the downstream signalling events mediated by these peptides remain to be elucidated. Here, we aimed to assess the mechanisms by which a validated peptide triagonist for GLP-1/GIP/GCG receptors (IUB447) stimulates insulin secretion in murine pancreatic islets.
View Article and Find Full Text PDFCardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration.
Minerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDFPreoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Following Operative Ankle Fracture Repair in Patients With Type 2 Diabetes: A National Database Study.
Foot Ankle Int
September 2025
Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in management of type 2 diabetes mellitus (T2DM) and obesity. Beyond glycemic control, these agents may influence orthopaedic outcomes. This study aimed to assess the relationship between preoperative GLP-1 RA use and postoperative complications in T2DM patients undergoing operative ankle fracture repair.
View Article and Find Full Text PDF